PETALING JAYA: Leading pharmaceutical player Pharmaniaga Bhd
’s catalyst for growth will be its manufacturing business and projections of a higher revenue contribution from Indonesia, according to MIDF Research.
The research house has initiated a “buy” call with a target price of RM5.80, stating that apart from increased order from the Government and newly introduced generic drugs in the market, the manufacturing segment will be Pharmaniaga’s future earnings driver.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
